Overview

A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of 2 doses of LY2189265 on blood pressure and heart rate using 24-hour ambulatory blood pressure monitoring (ABPM), in participants with type 2 diabetes mellitus treated with oral antihyperglycemic medications (OAMs).
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Dulaglutide